European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease (EUROASPIRE VI)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorEuropean Society of Cardiology

About this trial

The goal of this observational study is to provide a unique European picture of preventive action by cardiologists, other specialists and primary care physicians looking after patients with coronary heart disease (CHD), individuals at high cardiovascular disease risk and all those with hypertension, dyslipidaemia (including familial hypercholesterolaemia), diabetes and dysglycaemia and chronic kidney disease (CKD) and determine whether the European guidelines on cardiovascular disease prevention, hypertension, lipids, diabetes and chronic kidney disease are being followed.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients having signed an informed Consent

Patients aged from 18 years old at the time of identification

At least six and at most 24 months elapsed between the index event (the recruiting diagnostic or treatment criteria below) and the date of interview

Coronary patients: Acute coronary events (acute coronary syndrome {STEMI or NSTEMI}, unstable angina) or an emergency or elective revascularisation for coronary artery disease (CABG, PCI)

Disqualifiers

Patients living outside defined geographical areas

Patients admitted to hospital from outside the geographical area or under the care of cardiologists in hospitals that do not participate in EUROASPIRE VI

Trial population

The study population is all consenting adult patients presenting with high risk of cardiovascular diseases identified by general practices medical note and all consenting adult patients presenting with coronary disease seen in clinic.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

8,000 Participants
are grouped into 2 trial groups
Group A: Hospital Arm
Group B: Primary Care Arm

Trial outcomes

Primary outcomes

1

Proportions of hospital coronary patients and high risk individuals in primary care achieving European lifestyle, risk factors and therapeutic targets for cardiovascular disease prevention

The management of risk in terms of lifestyle intervention and the use of drug therapies will be evaluated in relation to the lifestyle and therapeutic goals defined in the national and European guidelines on cardiovascular disease prevention.

Time frame
30 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

European Society of Cardiology

Lead sponsor

National Institute for Prevention and Cardiovascular Health, Ireland

Collaborator